AIM
UTHR icon

Advyzon Investment Management’s United Therapeutics UTHR Stock Holding History

Advyzon Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481K Buy
887
+386
+77% +$217K 0.03% 489
2026
Q1 		$297K Buy
501
+34
+7% +$16.9K 0.03% 536
2025
Q4 		$228K Buy
+467
New +$217K 0.03% 526

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Advyzon Investment Management's UTHR Position: Q2 2026 in Review

Advyzon Investment Management increased its United Therapeutics (UTHR) stake by 77% in Q2 2026, buying an estimated $217K and bringing the position to 887 shares worth $481K. The position accounts for 0.03% of the portfolio, ranked #489.

Advyzon Investment Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Advyzon Investment Management held 887 shares of United Therapeutics worth $481K as of Q2 2026.
  • Advyzon Investment Management bought 386 United Therapeutics shares in Q2 2026, an estimated $217K.
  • United Therapeutics made up 0.03% of Advyzon Investment Management's portfolio in Q2 2026, its #489 holding.
  • Advyzon Investment Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Advyzon Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.